Update on the management of attention-deficit/hyperactivity disorder in children and adults: Patient considerations and the role of lisdexamfetamine

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 943-948

  Cowles, Brian J ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

ADHD; Attention deficit hyperactivity disorder; Lisdexamfetamine; Stimulants; Vyvanse

Indexed keywords

AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; LISDEXAMFETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ADULT DISEASE; AGITATION; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DECREASED APPETITE; DRUG ABUSE; DRUG CHOICE; DRUG EFFICACY; DYSTONIA; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; NERVOUSNESS; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION;

EID: 77949442458     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s6733     Document Type: Review

References (33)

1. Bloom B, Cohen RA, Freeman G. Summary health statistics for US children: National Health Interview Survey, 2007. Vital Health Stat. 2009;10:1-80.
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
3. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942-948.
4. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
5. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebocontrolled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63:981-989.
6. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11:625-639.
7. Vyvanse (lisdexamfetamine dimesylate) [Package insert]. Wayne, PA: Shire Pharmaceuticals, April 2008.
8. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816-818.
9. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol. 1995;23:729-749.
10. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007;32:631-642.
11. Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs. 2008;22:603-611.
12. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy. 2005;25:909-917.
13. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebocontrolled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:1364-1373.
14. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450-463.
15. Kaloyanides KB, McCabe SE, Cranford JA, Teter CJ. Prevalence of illicit use and abuse of prescription stimulants, alcohol, and other drugs among college students: relationship with age at initiation of prescription stimulants. Pharmacotherapy. 2007;27:666-674.
16. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21-31.
17. Setlik J, Bond GR, Ho M. Adolescent Prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics. 2009 Aug 24. [Epub ahead of print].
18. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998;94:127-152.
19. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extendedrelease in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970-976.
20. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, singlecentre, phase I study in healthy adult volunteers. Clin Drug Investig. 2008;28:745-755.
21. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 2008;24:33-40.
22. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol. 2008;48:293-302.
23. Lopez FA, Ginsberg LD, Arnold V. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/ hyperactivity disorder: a secondary analysis. Postgrad Med. 2008;120:89-102.
24. Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
25. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008;13:614-620.
26. Spiller HA, Griffith JR, Anderson DL, Weber JA, Aleguas A. Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine. Ann Pharmacother. 2008;42:1142-1143.
27. Adler LA, Goodman D, Weisler R, Hamdani M, Roth T. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/ hyperactivity disorder. Behav Brain Funct. 2009;5:34.
28. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407-2423.
29. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451-453.
30. Jasinski D, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23:410-418.
31. Jasinski D, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23:419-427.
32. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule. Fed Reg. 2007;72:24532-24534.
33. Vermont Disclosure Act. Shire Pharmaceuticals, 2009. URL: http://www.shirepricing.com/Documents/VYVANSE-long-form.pdf. Accessed Nov 12, 2009.